

**FULCRUM THERAPEUTICS, INC.**  
26 Landsdowne Street  
Cambridge, MA 02139

**VIA EDGAR**

April 24, 2024  
United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, DC 20549

**Re: Fulcrum Therapeutics, Inc.**  
**Acceleration Request for Registration Statement on Form S-3**  
**Filed February 27, 2024**  
**File No. 333-277419**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Fulcrum Therapeutics, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to April 25, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Marianne Sarrazin of Goodwin Procter LLP at (415) 733-6134.

Fulcrum Therapeutics, Inc.

/s/ Alan Musso  
\_\_\_\_\_  
Alan Musso

cc: Alan Musso, *Fulcrum Therapeutics, Inc.*  
Curt Oltmans, *Fulcrum Therapeutics, Inc.*  
Mitchell Bloom, *Goodwin Procter LLP*  
Marianne Sarrazin, *Goodwin Procter LLP*